Skip to main content

Thank you for visiting You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

Volume 2 Issue 9, September 2021

Profiling immune responses to combination neoadjuvant therapy for hepatocellular carcinoma

High-dimensional profiling of tumor biopsies identifies features of the immune microenvironment associated with response to neoadjuvant treatment with a combination of the targeted kinase inhibitor cabozantinib and the immune-checkpoint inhibitor nivolumab, in a phase 1b clinical trial for hepatocellular carcinoma.

See Ho et al.

Image: Soren Charmsaz, Nicole Gross, and Won Jin Ho (Johns Hopkins University School of Medicine, Baltimore, MD, USA). Cover Design: Allen Beattie.


  • Advertisement

Top of page ⤴

News & Views

  • Combining radiation and immune checkpoint blockade is a promising treatment strategy, yet the mechanisms and optimal dosing strategies are not well known. A new study finds that a specific radiation dose can activate secretory club cells to promote the anti-tumor effects of radiotherapy combined with immunotherapy in NSCLC.

    • Ralph R. Weichselbaum
    • Sean P. Pitroda
    News & Views
  • CAR T cell therapies have made great strides in the clinic; however, multiple hurdles limit the efficacy of this approach for solid tumors. A new study has developed an optimized, dual-targeting CAR T cell that overcomes several of these challenges by enhancing T cell persistence and reducing therapy escape due to antigen loss.

    • Tiffany R. King-Peoples
    • Avery D. Posey Jr.
    News & Views
  • Pseudouridine is the most abundant RNA modification, but its biological role remains poorly understood. A study now finds dysregulated pseudouridine synthase PUS7 in glioblastoma and demonstrates that pharmacological inhibition of PUS7 leads to reduced tumorigenesis, which underpins the therapeutic potential of targeting epitranscriptomic regulators in cancer.

    • Virginia Morón-Calvente
    • Sandra Blanco
    News & Views
Top of page ⤴


  • Ding and colleagues discuss the era of pan-cancer analysis, covering the fundamental insights gained, unique opportunities and challenges, and the future of such approaches in the basic and clinical space.

    • Feng Chen
    • Michael C. Wendl
    • Li Ding
    Review Article
Top of page ⤴


Top of page ⤴

Amendments & Corrections

Top of page ⤴


Quick links